Condition: Neuroblastoma Recurrent · Neuroblastoma · Sponsor: Jakob Stenman
The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the experience from the previous LuDO Trial and utilises an intensified dosing schedule to deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often rapidly progressing disease. This strategy requires a readiness for autologous stem cell transplantation in all patients, but is not anticipated to increase the risk of long-term sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after ende of treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with 68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.
This description comes directly from the study's public registry record.
Jakob Stenman, MD PhD · (0)51770000 · jakob.stenman@sll.se
Kleopatra Georgantzi, MD · (0)51770000 · kleopatra.georgantzi@sll.se
Always discuss trial participation with your own doctor first.
| Rigshospitalet | Copenhagen, Copenhagen, Denmark | Recruiting |
| Vilnius University Hospital | Vilnius, Vilnius County, Lithuania | Recruiting |
| Princess Maxima Center for Pediatric Oncology | Utrecht, Utrecht, Netherlands | Recruiting |
| Oslo University Hospital, Rikshospitalet | Oslo, Oslo, Norway | Recruiting |
| Karolinska University Hospital | Stockholm, Stockholm County, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04903899